The clinical treatment strategy for gastric cancer is based on surgery, chemotherapy, radiotherapy, molecular targeting of human epidermal growth factor receptor 2 monoclonal antibody and immunotherapy such as programmed cell death ligand 1 inhibitors, but the prognosis of GC patients with advanced stages remains poor. Here, ERBB2 is linked to gastric cancer.